CPhI Worldwide; shortlisted finalists for the 2015 Pharma Awards

CPhI Worldwide; shortlisted finalists for the 2015 Pharma Awards

Winners from all 7 categories will be unveiled live at the event in Madrid

Finalists by category

·         Innovation in Supply Chain & Logistic Management: Aesica and Trace Link

·         Best Innovation in Manufacturing Technology – in cooperation with Pharmaceutical Technology: Harro Hoefliger, Palladio and Viavi

·         Best Innovation in Packaging: Sulzer, Catalent and Nemera

·         Best Innovation in APIs and Excipients: OMYA International AG, Aurena and NOF Corporation

·         Excellence in Partnering & Outsourcing – in cooperation with Pharmaceutical Outsourcing Magazine:  Centroflora and Johnson Matthey

·         Best Innovation in Process and Formulation Development: Supercritical Solutions, Codexis and Catalent

·         CEO of the Year in cooperation with PharmaBoardroom: just one winner to be confirmed at event

Amsterdam, 23 September 2015: CPhI Worldwide, (#cphiww) organised by UBM EMEA, today announces the finalists of the prestigious 2015 CPhI Pharma Awards. This year's entries include innovations and new service offerings from across the entire spectrum of the pharmaceutical supply chain, honouring companies and individuals driving the industry forward.

The Awards had a record number of entries and launched four new categories this year, covering: 'Best Innovation in Packaging'; 'Best Innovation in Process and Formulation Development'; 'Excellence in Partnering & Outsourcing'; 'Best Innovation in APIs and Excipients' (new); 'Innovation in Supply Chain & Logistic Management' (new); 'Best Innovation in Manufacturing Technology' (new); and 'CEO of the Year' (new).

All 16 finalists will now give an in-depth presentation to the jury panel on Tuesday 13th October at CPhI Worldwide, before the winners are announced live during the show.

Technologies shortlisted for the Awards include a multi-dose dry powder inhaler, near infrared spectrometers and pill compliance systems. Packaging innovations include glass-free vials, nasal spray pumps and modular unit dose packaging. Across process and formulation development entries include softgel capsules, engineered enzymes for shorter synthesis, and lipid coating agents.

In the pharmaceutical supply chain, innovative models for track and trace technologies and a unique supply chain management solution (one CDMO managing others) have been featured. Partnering and outsourcing remains an essential component of CPhI and our finalists this year include a small/large pharma partnership for plant derived APIs, and a CRO/pharma partnership that accelerated clinical development.

For APIs and excipients, technological innovations include methods for the direct deposition of liquids and functional lipids for nano-particle encapsulation of small molecules. Finally, for CEO of the year, CPhI will announce one eagerly anticipated winner live from the show. 

Rutger Oudejans, CPhI Brand Director: "The CPhI Pharma Awards have grown in scope and breadth as the show has expanded to incorporate all parts of the pharmaceutical supply chain. This year, we received a remarkable response from the industry, demonstrating the high regard with which these Awards are held and the sheer number of innovations now emerging from pharma.

In total, there were 70 entries, and the feedback from our judging panel is that the quality of submissions has grown enormously, making the shortlisting process incredibly difficult. As such, all of our finalists deserve commendations for the role in which they are playing in driving pharma forward through developing solutions to the industry's most pressing needs. CPhI Worldwide is now firmly established as a global platform for recognising and celebrating pharma's most dynamic companies."

For a full list of the finalists and more information on the CPhI Pharma Awards, please visit: http://www.cphi.com/awards/home

-ENDS-

Notes to editors

About CPhI

CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, South East Asia, Turkey and Russia and co-locates with ICSE for contract services, P-MEC for machinery, equipment & technology, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com.

For more information visit: www.cphi.com

The UBM EMEA annual schedule of Pharmaceutical events includes; CPhI Korea (7-9 September, 2015 at the COEX Hall D- Seoul, South Korea); CPhI, ICSE, P-MEC and InnoPack Worldwide (13-15 October 2015, IFEMA- Feria de Madrid, Spain); CPhI, P-MEC, ICSE and BioPh India (1-3 December, 2015 at the Bombay Convention and Exhibition Centre, Mumbai, India); CPhI, P-MEC and Innopack South East Asia (06-08 April, 2016 at the Jakarta International Expo- Jakarta, Indonesia); CPhI, ICSE, P-MEC, BioPh and InnoPack Japan (20-22 April, 2016 at the Big Sight Exhibition Centre- Tokyo); CPhI Istanbul (1-3 June, 2016 at the ICC Istanbul Congress Center, Istanbul, Turkey); CPhI China and P-MEC (21-23 June, 2016 at SNIEC, Shanghai, China).

About UBM EMEA

UBM EMEA connects people and creates opportunities for companies across five continents to develop new business, meet customers, launch new products, promote their brands, and expand their market. Through premier brands such as TFM&A, Internet World, IFSEC, MD&M, CPhI, Cruise Shipping Miami, the Concrete Show, and many others, UBM Live exhibitions, conferences, awards programs, publications, Websites, and training and certification programs are an integral part of the marketing plans of companies across more than 20 industry sectors.

 

For media enquiries, please contact:

Alex Heeley or Tristan Jervis   

De Facto Communications

T: +44 207 203 6745 / 6740

E: [email protected] / [email protected]

 

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.